We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · August 10, 2020

Combination Nivolumab and Ipilimumab Immunotherapy in Patients With Advanced Biliary Tract Cancers

JAMA Oncology

 

Additional Info

Disclosure statements are available on the authors' profiles:

JAMA Oncology
Evaluation of Combination Nivolumab and Ipilimumab Immunotherapy in Patients With Advanced Biliary Tract Cancers: Subgroup Analysis of a Phase 2 Nonrandomized Clinical Trial
JAMA Oncol 2020 Jul 30;[EPub Ahead of Print], O Klein, D Kee, A Nagrial, B Markman, C Underhill, M Michael, L Jackett, C Lum, A Behren, J Palmer, NC Tebbutt, MS Carlino, J Cebon

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading